In response to the critical shortage of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) and rapidly declining supply of methotrexate, the Food and Drug Administration took proactive steps to increase available supplies for patients in the U.S.

Under the FDA's exercise of enforcement discretion, the chemotherapeutic drug Lipodox will be imported as an alternative to Doxil, which is used in multiple treatment regimens, including treatment of ovarian cancer after failure of platinum-based chemotherapy. The drug is also indicated for use in AIDS-related Kaposi's sarcoma and multiple myeloma. The